Camille Lefevre1, Laure B Bindels2,3. 1. Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Avenue Mounier 73, B1.73.11, 1200, Brussels, Belgium. 2. Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Avenue Mounier 73, B1.73.11, 1200, Brussels, Belgium. laure.bindels@uclouvain.be. 3. Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Avenue Pasteur 6, 1300, Wavre, Belgium. laure.bindels@uclouvain.be.
Abstract
PURPOSE OF REVIEW: This review aims to summarize the recent findings about the contribution of the gut microbiome to muscle pathophysiology and discuss molecular pathways that may be involved in such process. Related findings in the context of cancer cachexia are outlined. RECENT FINDINGS: Many bacterial metabolites have been reported to exert a beneficial or detrimental impact on muscle physiology. Most of the evidence concentrates on short-chain fatty acids (SCFAs), with an emerging role for bile acids, bacterial amino acid metabolites (bAAms), and bacterial polyphenol metabolites. Other molecular players worth considering include cytokines, hormones, lipopolysaccharides, and quorum sensing molecules. The current literature clearly establishes the ability for the gut microbiome to modulate muscle function and mass. The understanding of the mechanisms underlying this gut-muscle axis may lead to the delivery of novel therapeutic tools to tackle muscle wasting in cancer cachexia, chronic kidney disease, liver fibrosis, and age-related sarcopenia.
PURPOSE OF REVIEW: This review aims to summarize the recent findings about the contribution of the gut microbiome to muscle pathophysiology and discuss molecular pathways that may be involved in such process. Related findings in the context of cancer cachexia are outlined. RECENT FINDINGS: Many bacterial metabolites have been reported to exert a beneficial or detrimental impact on muscle physiology. Most of the evidence concentrates on short-chain fatty acids (SCFAs), with an emerging role for bile acids, bacterial amino acid metabolites (bAAms), and bacterial polyphenol metabolites. Other molecular players worth considering include cytokines, hormones, lipopolysaccharides, and quorum sensing molecules. The current literature clearly establishes the ability for the gut microbiome to modulate muscle function and mass. The understanding of the mechanisms underlying this gut-muscle axis may lead to the delivery of novel therapeutic tools to tackle muscle wasting in cancer cachexia, chronic kidney disease, liver fibrosis, and age-related sarcopenia.
Authors: Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield Journal: Ann Med Date: 2018-09-12 Impact factor: 4.709
Authors: Matthew Maddocks; Jane Hopkinson; John Conibear; Annie Reeves; Clare Shaw; Ken C H Fearon Journal: Curr Opin Support Palliat Care Date: 2016-12 Impact factor: 2.302
Authors: Gabriele Berg; Daria Rybakova; Doreen Fischer; Tomislav Cernava; Marie-Christine Champomier Vergès; Trevor Charles; Xiaoyulong Chen; Luca Cocolin; Kellye Eversole; Gema Herrero Corral; Maria Kazou; Linda Kinkel; Lene Lange; Nelson Lima; Alexander Loy; James A Macklin; Emmanuelle Maguin; Tim Mauchline; Ryan McClure; Birgit Mitter; Matthew Ryan; Inga Sarand; Hauke Smidt; Bettina Schelkle; Hugo Roume; G Seghal Kiran; Joseph Selvin; Rafael Soares Correa de Souza; Leo van Overbeek; Brajesh K Singh; Michael Wagner; Aaron Walsh; Angela Sessitsch; Michael Schloter Journal: Microbiome Date: 2020-06-30 Impact factor: 14.650